Effectiveness of Tildrakizumab in the Long-Term Treatment of Plaque Psoriasis: A Retrospective, Multicenter Analysis Over 76 Weeks

IF 3.4 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2025-09-27 DOI:10.1155/dth/6691386

Caroline Glatzel, Janik Fleißner, Theodhora Shuti, Valerie Glatzel, Tassilo Dege, Astrid Schmieder, Matthias Goebeler, Michael Sticherling, Andreas Kerstan

{"title":"Effectiveness of Tildrakizumab in the Long-Term Treatment of Plaque Psoriasis: A Retrospective, Multicenter Analysis Over 76 Weeks","authors":"Caroline Glatzel, Janik Fleißner, Theodhora Shuti, Valerie Glatzel, Tassilo Dege, Astrid Schmieder, Matthias Goebeler, Michael Sticherling, Andreas Kerstan","doi":"10.1155/dth/6691386","DOIUrl":null,"url":null,"abstract":"Background: Psoriasis is a chronic inflammatory disease affecting skin and patients’ quality of life. Tildrakizumab is an IL-23p19-inhibitor approved for treatment of moderate-to-severe plaque psoriasis.Objective: To evaluate the effectiveness of tildrakizumab in daily practice in a heterogeneous cohort of patients with psoriasis often accompanied by comorbid (especially cardiometabolic) diseases.Methods: We conducted a retrospective analysis at two university outpatient clinics in Germany (April 2018 to June 2024), collecting data on patient characteristics, comorbidities, prior therapies, and treatment response.Results: The effectiveness analysis included 111 patients with psoriasis treated with tildrakizumab. Median PASI was 12.6 (IQR 11.0–18.6) at baseline and decreased to 6.0 (IQR 1.0–10.4) at Week 4, to 1.8 (IQR 1.0–10.4) at Week 16, and median PASI 0.00 (IQR 0.0–0.0) at Week 76. Median PASI < 3 was achieved by 64.6% at Week 16, 79.7% at Week 52 and 94.4% at Week 76 and PASI < 5 by 83.3% at Week 16, 94.2% at Week 52, and 100% at Week 76. The proportion achieving PASI75, PASI90, and PASI100 at Week 76 was 97.2%, 83.3%, and 58.3%. Patients with arterial hypertension (AHT) showed a lower PASI response compared to those without AHT, starting from Week 28 (p = 0.035) and continuing throughout the follow-up period. However, a detailed analysis indicates that patients with AHT also achieved PASI < 3 at Week 28 and beyond. Furthermore, patients with at least one cardiovascular risk factor (CRF: obesity, dyslipidemia, AHT, or type 2 diabetes mellitus, [46.8%]) demonstrated a less pronounced PASI response at Weeks 16, 28, and 64 compared to patients without such risk factors (pwk16 = 0.023; pwk28 = 0.012; pwk64 = 0.014). Median DLQI at baseline was 16.0 (IQR 9.5–22.0) and improved to 3.0 (IQR 1.0–8.0) at 4–16 weeks.Conclusion: This analysis confirmed effectiveness of tildrakizumab in a real-world setting, with notable improvements in PASI response observed in a heterogeneous patient cohort and a high level of quality of life improvement. It is noteworthy that patients with AHT and other CRF demonstrated lower treatment responses, indicating that these comorbidities may exert an influence on outcomes.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6691386","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/6691386","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Psoriasis is a chronic inflammatory disease affecting skin and patients’ quality of life. Tildrakizumab is an IL-23p19-inhibitor approved for treatment of moderate-to-severe plaque psoriasis.

Objective: To evaluate the effectiveness of tildrakizumab in daily practice in a heterogeneous cohort of patients with psoriasis often accompanied by comorbid (especially cardiometabolic) diseases.

Methods: We conducted a retrospective analysis at two university outpatient clinics in Germany (April 2018 to June 2024), collecting data on patient characteristics, comorbidities, prior therapies, and treatment response.

Results: The effectiveness analysis included 111 patients with psoriasis treated with tildrakizumab. Median PASI was 12.6 (IQR 11.0–18.6) at baseline and decreased to 6.0 (IQR 1.0–10.4) at Week 4, to 1.8 (IQR 1.0–10.4) at Week 16, and median PASI 0.00 (IQR 0.0–0.0) at Week 76. Median PASI < 3 was achieved by 64.6% at Week 16, 79.7% at Week 52 and 94.4% at Week 76 and PASI < 5 by 83.3% at Week 16, 94.2% at Week 52, and 100% at Week 76. The proportion achieving PASI75, PASI90, and PASI100 at Week 76 was 97.2%, 83.3%, and 58.3%. Patients with arterial hypertension (AHT) showed a lower PASI response compared to those without AHT, starting from Week 28 (p = 0.035) and continuing throughout the follow-up period. However, a detailed analysis indicates that patients with AHT also achieved PASI < 3 at Week 28 and beyond. Furthermore, patients with at least one cardiovascular risk factor (CRF: obesity, dyslipidemia, AHT, or type 2 diabetes mellitus, [46.8%]) demonstrated a less pronounced PASI response at Weeks 16, 28, and 64 compared to patients without such risk factors (p_wk16 = 0.023; p_wk28 = 0.012; p_wk64 = 0.014). Median DLQI at baseline was 16.0 (IQR 9.5–22.0) and improved to 3.0 (IQR 1.0–8.0) at 4–16 weeks.

Conclusion: This analysis confirmed effectiveness of tildrakizumab in a real-world setting, with notable improvements in PASI response observed in a heterogeneous patient cohort and a high level of quality of life improvement. It is noteworthy that patients with AHT and other CRF demonstrated lower treatment responses, indicating that these comorbidities may exert an influence on outcomes.

Abstract Image

查看原文本刊更多论文

Tildrakizumab长期治疗斑块型银屑病的有效性：一项超过76周的回顾性多中心分析

背景：银屑病是一种影响皮肤和患者生活质量的慢性炎症性疾病。Tildrakizumab是一种il -23p19抑制剂，被批准用于治疗中度至重度斑块性银屑病。目的：评估tildrakizumab在银屑病患者（通常伴有合并症（特别是心脏代谢）疾病）的异质队列患者的日常实践中的有效性。方法：我们对德国两所大学门诊（2018年4月至2024年6月）进行了回顾性分析，收集了患者特征、合并症、既往治疗和治疗反应的数据。结果：疗效分析纳入111例tildrakizumab治疗的银屑病患者。基线时PASI中位数为12.6 (IQR为11.0-18.6)，第4周降至6.0 (IQR为1.0-10.4)，第16周降至1.8 (IQR为1.0-10.4)，第76周的PASI中位数为0.00 （IQR为0.0-0.0）。PASI <； 3在第16周达到64.6%，第52周达到79.7%，第76周达到94.4%,PASI <； 5在第16周达到83.3%，第52周达到94.2%，第76周达到100%。在第76周达到PASI75、PASI90和PASI100的比例分别为97.2%、83.3%和58.3%。从第28周开始，动脉高血压（AHT）患者的PASI反应较无AHT患者低（p = 0.035），并持续到整个随访期间。然而，一项详细的分析表明，AHT患者在第28周及以后也达到了PASI <； 3。此外，至少有一种心血管危险因素（CRF：肥胖、血脂异常、AHT或2型糖尿病，[46.8%]）的患者在第16、28和64周的PASI反应较不明显（pwk16 = 0.023; pwk28 = 0.012; pwk64 = 0.014）。基线时DLQI中位数为16.0 (IQR 9.5-22.0)，在4-16周时改善至3.0 （IQR 1.0-8.0）。结论：该分析证实了tildrakizumab在现实世界环境中的有效性，在异质患者队列中观察到PASI反应的显着改善和高水平的生活质量改善。值得注意的是，AHT和其他CRF患者表现出较低的治疗反应，表明这些合并症可能对结果产生影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.